Cabaletta Bio, a Phase 1-ready biotech engineering T cell therapies for autoimmune diseases, filed on Monday with the SEC to raise up to $100 million in an initial public offering.
The Philadelphia, PA-based company was founded in 2017. It plans to list on the Nasdaq under the symbol CABA. Morgan Stanley, Cowen and Evercore ISI are the joint bookrunners on the deal. The company filed confidentially in August 2019. No pricing terms were disclosed.
